Literature DB >> 23294530

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.

Valerie Waters1, Eshetu G Atenafu, Annie Lu, Yvonne Yau, Elizabeth Tullis, Felix Ratjen.   

Abstract

BACKGROUND: Chronic Stenotrophomonas maltophilia infection is an independent risk factor for severe pulmonary exacerbations in cystic fibrosis (CF) patients. The goal of this study was to determine the effect of chronic S. maltophilia infection on mortality and the need for lung transplantation in a longitudinal study of children and adults with CF.
METHODS: This was a cohort study of CF patients from the Hospital for Sick Children and St Michael's Hospital (Toronto, Canada) from 1997 to 2008. A Cox Regression model was used to estimate the hazard ratio (HR) to time of death or lung transplantation adjusting for age, gender, genotype, pancreatic status, CF related diabetes (CFRD), forced expiratory volume in 1 s (FEV1), body mass index, number of pulmonary exacerbations, Pseudomonas aeruginosa, Burkholderia cepacia complex, Aspergillus and chronic S. maltophilia infection.
RESULTS: A total of 687 patients were followed over the 12 year study period; 95 patients underwent a lung transplantation (of which 26 died) and an additional 49 patients died (total 144 events). In a Cox Regression model adjusting for baseline FEV1, baseline infection with B. cepacia complex (HR 1.72, 95% CI 1.09-2.71) and baseline chronic S. maltophilia infection (HR 2.80, 95% CI 1.65-4.76) were significantly associated with death or lung transplant. However, in a time-varying model, infection with B. cepacia complex and chronic S. maltophilia infection were no longer significant.
CONCLUSIONS: Baseline chronic S. maltophilia infection is associated with an almost three-fold increased risk of death or lung transplant in CF patients. It is still unclear, however, whether chronic S. maltophilia infection is simply a marker of severity of disease and ultimate mortality or whether it is causally related to disease progression.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Lung transplantation; Mortality; Stenotrophomonas maltophilia

Mesh:

Year:  2013        PMID: 23294530     DOI: 10.1016/j.jcf.2012.12.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  38 in total

Review 1.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

2.  Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice.

Authors:  Hannah Grazul; L Leann Kanda; David Gondek
Journal:  Gut Microbes       Date:  2016-03-10

3.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

4.  In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors:  Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

6.  Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.

Authors:  M Biagi; X Tan; T Wu; M Jurkovic; A Vialichka; K Meyer; R E Mendes; E Wenzler
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

Review 7.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

8.  Microbial Interactions in the Cystic Fibrosis Airway.

Authors:  Ann M Granchelli; Frederick R Adler; Ruth H Keogh; Christiana Kartsonaki; David R Cox; Theodore G Liou
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

Review 9.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

10.  Epidemiology and outcomes of Stenotrophomonas maltophilia and Burkholderia cepacia infections among trauma patients of India: a five year experience.

Authors:  Nonika Rajkumari; Purva Mathur; Amit K Gupta; Kumkum Sharma; Mahesh C Misra
Journal:  J Infect Prev       Date:  2014-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.